Tocagen Inc (NASDAQ:TOCA) dropped 9.7% during trading on Thursday . The company traded as low as $0.55 and last traded at $0.56, approximately 948,610 shares changed hands during trading. An increase of 124% from the average daily volume of 422,823 shares. The stock had previously closed at $0.62.

TOCA has been the topic of a number of recent analyst reports. Citigroup cut Tocagen from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $20.00 to $1.00 in a research note on Friday, September 13th. Zacks Investment Research upgraded Tocagen from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a research note on Wednesday, September 18th. Robert W. Baird cut Tocagen from an “outperform” rating to a “neutral” rating in a research note on Thursday, September 12th. LADENBURG THALM/SH SH lowered Tocagen from a “buy” rating to a “neutral” rating in a report on Thursday, September 12th. Finally, ValuEngine raised Tocagen from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Nine equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $10.26.

The firm has a fifty day moving average of $2.09 and a two-hundred day moving average of $5.92. The company has a market cap of $14.90 million, a PE ratio of -0.23 and a beta of 3.90. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.86.

Tocagen (NASDAQ:TOCA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.04. Tocagen had a negative return on equity of 115.81% and a negative net margin of 300.42%. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.50 million. Sell-side analysts expect that Tocagen Inc will post -2.64 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. increased its holdings in Tocagen by 0.7% in the 2nd quarter. BlackRock Inc. now owns 1,672,165 shares of the company’s stock worth $11,171,000 after acquiring an additional 11,152 shares during the last quarter. Vanguard Group Inc. grew its holdings in Tocagen by 0.6% during the 2nd quarter. Vanguard Group Inc. now owns 1,068,135 shares of the company’s stock valued at $7,135,000 after buying an additional 6,260 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Tocagen by 5.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 476,684 shares of the company’s stock valued at $3,074,000 after buying an additional 23,293 shares in the last quarter. Sphera Funds Management LTD. purchased a new position in Tocagen during the 1st quarter valued at about $1,304,000. Finally, Acadian Asset Management LLC grew its holdings in Tocagen by 151.0% during the 2nd quarter. Acadian Asset Management LLC now owns 92,450 shares of the company’s stock valued at $618,000 after buying an additional 55,621 shares in the last quarter. 35.38% of the stock is owned by institutional investors.

Tocagen Company Profile (NASDAQ:TOCA)

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Recommended Story: Understanding debt-to-equity ratio in fundamental analysis

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.